ReviewFrontiers in oncology2025
Epstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.Infectious diseases of poverty · 2026Article
- Epstein-Barr virus infection shapes the genetic, transcriptomic, and immune microenvironment landscape of Burkitt lymphoma.Infectious agents and cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) is a ubiquitous human gamma-herpesvirus causally linked to a diverse spectrum of lymphoid malignancies. This review provides a comprehensive overview of EBV-associated lymphomas, encompassing their global epidemiology, the intricate pathogenesis driven by viral latency proteins and complex host immune interactions, and the varied clinical presentations of distinct subtypes. We delve into the detailed pathological features, molecular characteristics, and diagnostic strategies for classic Hodgkin lymphoma (cHL), Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), post-transplant lymphoproliferative disorder (PTLD), and extra-nodal NK/T-cell lymphoma, nasal type (ENKTL). Current subtype-specific treatment paradigms are critically evaluated, along with a thorough exploration of emerging therapeutic avenues, including novel immunotherapeutic approaches such as immune checkpoint inhibitors, adoptive cell therapies like EBV-specific cytotoxic T lymphocytes and chimeric antigen receptor T-cells (CAR-T), and targeted molecular therapies. Finally, we highlight the persistent challenges, critical knowledge gaps, and promising future prospects, including preventative and therapeutic vaccine strategies, aimed at optimizing diagnostic precision and improving long-term outcomes for patients afflicted with these heterogeneous and often aggressive diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.